FLCCC | Front Line COVID-19 Critical Care Alliance
Latest Updates

FLCCC Files Amicus Brief in Gahl v. Aurora Health

Published On: December 15, 2022|
Print Friendly, PDF & Email

WASHINGTON, D.C. – On December 15, the FLCCC filed its amicus brief in the Supreme Court of Wisconsin for the lawsuit against Aurora Health Care, Inc. for refusing patients’ access to a safe and potentially lifesaving treatment for COVID-19.

The lawsuit, Gahl v. Aurora Health, was brought by Allen Gahl, on behalf of his uncle, John Zingsheim, who was denied access to ivermectin in October 2021 after the hospital had placed Mr. Zingsheim on a ventilator in the ICU without offering further effective treatment for COVID-19 or hope for survival. Mr. Gahl initiated the lawsuit in Waukesha County Circuit Court, which ultimately ordered the hospital to allow his uncle’s doctor to administer the ivermectin treatment. The hospital, however, appealed the court’s decision to the Wisconsin Court of Appeals District II, which reversed the lower court’s ruling, opining that the lower court had no authority to compel the hospital to allow the use of ivermectin, even if administered by the patients outside doctor. The Amos Center for Justice & Liberty filed a petition for review which the Wisconsin Supreme Court granted in September.

“The FLCCC filed this brief to support Mr. Gahl’s case as we believe that patients, especially those in critical condition, should have access to all possible treatments. There was no medical reason for the hospital to deny Mr. Zingsheim access to ivermectin”, said Paul E. Marik, M.D., FCCM, FCCP, founding member of the FLCCC and former Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School.

“For the hospital to deny access to ivermectin, saying that it is ineffective and dangerous is absurd and easily disproved,” said Pierre Kory, M.D., M.P.A., president and chief medical officer of the FLCCC. “There are over 93 controlled trials, 73 of them are peer-reviewed trials, and 43 of them randomized controlled trials, all showing the safe and effective use of ivermectin in treating COVID-19. These trials amount to hundreds of thousands of patients being successfully treated with no severe side effects, which is consistent with the WHO’s finding that ivermectin ranks higher in safety than Tylenol or aspirin. It is unconscionable that a hospital charged with the care and well-being of its patients would deny access to such a treatment.”

The Wisconsin Supreme Court has agreed to hear the appeal of the Appellate Court decision and is expected to decide in 2023.

A copy of the FLCCC Amicus brief can be found here:


Explore Similar Stories

Go to Top